Published • loading... • Updated
Glaukos’ CXL Therapy, Epioxa, Meets Primary Endpoint in Phase 3 Clinical Trial
Summary by Eyewire+
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
Glaukos’ CXL Therapy, Epioxa, Meets Primary Endpoint in Phase 3 Clinical Trial
Key Takeaways Results of a phase 3 confirmatory pivotal trial for Epioxa (Glaukos), an FDA-approved therapy for keratoconus, were published in Ophthalmology and Therapy. Treatment with Epioxa led to a statistically significant improvement in Kmax at month 12 (-0.5 D improvement in Epioxa-treated eyes versus +0.4 D worsening in the sham group). The safety profile for Epioxa was favorable, with no serious ocular adverse events and mild, transien…
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
